Dr Gregory Glenn | President, Research and Development
Novavax | United States

Dr Gregory Glenn, President, Research and Development, Novavax

Dr. Glenn is a pioneer in vaccine delivery and adjuvants, and has brought several products from concept into clinical development, such as the travelers' diarrhea vaccine patch and an adjuvant patch for a pandemic influenza vaccine, developed under U.S. government contracts. He provided the scientific and technical leadership that led to the acquisition of IOMAI by Intercell in 2008. He has co-authored more than 150 research publications, scientific abstracts and presentations, and successful grant applications, and holds multiple U.S., European and other international patents. In addition, he is an associate editor of the journals Expert Review of Vaccines, and Human Vaccine, and was a board-certified pediatrician. Dr. Glenn received his Bachelor of Arts degree in Biology and Chemistry from Whitman College and his Doctor of Medicine degree from Oral Roberts University School of Medicine. He also completed the Medical Research Fellowship at the Walter Reed Army Institute of Research.

Appearances:



DC Co-conference Day 2 April 4 @ 11:40

The RSV F Nanoparticle Vaccine for Infants via Maternal Immunization in Phase 3: Rationale and Update

DC Co-conference Day 2 April 4 @ 3:25

Solutions for intradermal administration & clinical experience with the MicronJet600R

back to speakers